Must Capital Inc V.MUST.H

Very Encouraging To See That Someone Through Mackie

[illumination1]

has showed and anted up to grab 20,000 shares. This gives a lot of confidence in both Mackie as a market maker and the company's legitimate business which now the CEO and his team must continue to do their part to keep things going. Folks, contrary to what someone has raised of this not being a legitimate business and the CEO being a scammer I absolutely don't see it that way and apparently neither does Mackie. Everything in business takes time to diffuse through the market to gain market acceptance, unfortunately with the medical field it takes a bit longer than say something like a computer tech software/program but that doesn't make this or any other business illegitimate. With uro-nirs it took literally 6 months to get a Euromark certification where the company could sell in Europe and it never could get the US access. Medical devices go through three phases of testing usually and this can take up to a year so even if this company has been around for 2012 or 2014 whatever the case may be it does take time to even test devices to make sure they measure exactly what they are supposed as well as prove efficacy along with how accurate the device is. In one news release it is stated that this device is 93 percent accurate and that there would be further testing to see if the results could be replicated. All of this takes time and money so given where this company stands it really isn't doing all that badly. And if we take what I posted about Medmira at 25 million shares that were once trading at .50-$2.50 when it was a hot stock this has about two and a half times that amount so you would say .25 is two times and another .125 is the half you would get .125 as the difference this is what I would peg at this point this stock to be really worth although this is running a 17 million deficit which is a little tricky to account for. Nevertheless, if we knock this down by another 50% to .0625 I think this is actually a fair price for this equity right now--but that is in my best knowledge and opinion. Most of the times stocks trade based on potential not necessarily their financials but some do which are also getting unjustly low balled a bit even from what their low end acceptable range should be based on a very conservative revenue to share calculation for example pyr has 13 million in booked revenues and around 100 million shares roughly speaking--that would be .13 when you do the math and if you take a conservative 2 times revenue it should be .26 yet the equity is trading under that, when you take 3 times that would be .39. Most people take 5-10 times the revenue I usually don't but I won't complain any if my stock that I am invested in gets that 5-10 times benefit. At the end of the day a stock's worth is what people are willing to buy at. glta